Lopinavir/Tenofovir/Ritonavir

洛匹那韦/替诺福韦/利托那韦

Report date: 2024/01/02 20:03:52
NME

Base Information

Drug NameLopinavir/Tenofovir/Ritonavir
Drug Alias NameTLC-ARTTLC-ART 101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReverse transcriptase inhibitorsHuman immunodeficiency virus type 1 protease inhibitors
TargetsReverse transcriptaseHuman immunodeficiency virus type 1 protease
Therapy Area/IndicationsRetroviridae InfectionsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes TenofovirRitonavir
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Washington
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Washington
Inactive CompaniesN/A
Active IndicationsRetroviridae InfectionsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A